Saturday, October 3, 2026

Platinum Futures Over 4% Up In The Last 10 Sessions

Platinum Futures Over 4% Up In The Last 10 Sessions

(VIANEWS) - Platinum (PL) has been up by 4.55% for the last 10 sessions. At 11:52 EST on Thursday, 14 March, Platinum (PL) is $932.40.

Volume

Today's last reported volume for Platinum is 21437, 99.99% below its average volume of 7850941392.53.

Volatility

Platinum's last week, last month's, and last quarter's current intraday variation average was 1.69%, 0.91%, and 1.29%, respectively.

Platinum's highest amplitude of average volatility was 2.12% (last week), 1.19% (last month), and 1.29% (last quarter), respectively.

Commodity Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Platinum's commodity is considered to be oversold (<=20).

News about

  • According to FXStreet on Wednesday, 13 March, "Moreover, API Weekly Crude Oil Stock surprisingly fell in the week ending on March 8, with a decline of 5.521 million barrels, compared to an expected increase of 0.4 million barrels and the previous 0.423 million barrels. "
  • Crude oil staggers on Tuesday as bullish momentum gets cut short by EIA forecast shift. According to FXStreet on Tuesday, 12 March, "On the other hand, US Crude Oil production continues to break records, with American oil pumping reaching an all-time high of 12.9 million barrels per day in 2023, the most Crude Oil produced by any country, ever. ", "A steeper-than-expected decline in US Crude Oil stocks for the week ended March 8 from the American Petroleum Institute (API) saw a brief uptick in bullish momentum heading into the end of the American trading session. "

More news about Platinum (PL).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com